Pharma Pulse 7/11/24: Thermo Fisher Scientific Completes Acquisition of Olink, 7 Takeaways From the FTC Interim Report on PBMs & more
The latest news for pharma industry insiders.
A Harvard Business School Healthcare Alumni Association Q&A with Penn Center for Innovation’s Michael D. Moisel, MS, MBA.
Michael D. Poisel, MS, MBA, is responsible for managing Penn Center for Innovation (PCI) Ventures (PCIV), assisting the principal investigators with funding strategies, as well as mentoring developing companies. Prior to UPenn, he made investments in enterprise software and business services for NewSpring Capital, Apax Partners, and GE Capital.
7 Takeaways From the FTC Interim Report on PBMs
One theme of the Federal Trade Commission’s interim take on pharmacy benefit managers is vertical integration and how that affects competition in the industry.
Microsoft Quits OpenAI’s Board Amid Antitrust Scrutiny
Role of observer was part of a tie-up that is facing scrutiny in the U.S. and Europe.
Thermo Fisher Scientific Inc. announced that it has completed its acquisition of Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment.
The countdown begins! There's only one week left to showcase your groundbreaking work at the 2024 Pharmaceutical Executive® APEX Awards. Whether you're advancing patient care or leading innovative therapies, your contributions deserve recognition.
Don't miss this opportunity to join industry leaders on November 14th in NYC. Submit your entries today and be part of this prestigious event!
Enter now: https://ow.ly/jxKL50SuUrI
#PharmaMarketing #HealthcareInnovation #PEAPEXAwards
Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs
